secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010615
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q4 2022 net loss $11.8M, full year loss $41.0M; cash $99.3M
--------------------------------------------------------------------------------

- Net loss for Q4 2022 was $11.8M and full year 2022 was $41.0M.
- R&D expenses for full year 2022 were $29.5M vs $16.9M in 2021; G&A $12.8M vs $4.7M.
- Cash, cash equivalents and investments totaled $99.3M at Dec 31, 2022, expected to fund through mid-2024.
- Phase 2/3 pivotal trial for epetraborole in MAC lung disease approaching 60 sites; Phase 2 enrollment expected to complete mid-2023.
- Awarded up to $17.8M NIAID contract to develop epetraborole for melioidosis using non-dilutive funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/0000950170-23-010615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023010615/antx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer